The roles of phosphotyrosines-294,-404, and-451 in RET/PTC1-induced thyroid tumor formation

被引:27
作者
Buckwalter, TLF
Venkateswaran, A
Lavender, M
La Perle, KMD
Cho, JY
Robinson, ML
Jhiang, SM
机构
[1] Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA
关键词
RET/PTC1; mutagenesis; thyroid tumor; transgene;
D O I
10.1038/sj.onc.1205938
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RET/PTC1 is a rearranged form of the RET protooneogene detected in human papillary thyroid carcinomas. We previously showed that thyroid-targeted expression of RET/PTC1 leads to thyroid tumor formation in Tg-PTC1 transgenic mice. Signal transduction pathways mediated by phosphotyrosine 294, 404, or 451 in RET/PTC1 have been shown to be critical for RET-induced transforming activity in vitro. To investigate the contribution of these signaling pathways in RET/PTC1-induced thyroid tumor formation in vivo, we generated and characterized transgenic mice expressing thyroid-targeted RET/PTC1 mutants carrying a site-directed mutation changing tyrosine (Y) to phenylalanine (F) at the residue 294, 404, or 451. In contrast to the 100% tumor formation rate in Tg-PTC1 transgenic mice, tumor formation rates were significantly decreased in Tg-PTC1-Y294F (6%), Tg-PTC1-Y404F (41%), and Tg-PTC1-Y451F (30%) transgenic mice. This indicates that signaling pathways mediated by pY294, pY404, and pY451 do play a role in RET/PTC1-induced tumor formation. However, as tumors are still able to form in some mice within these three mutant transgenic groups, it indicates that none of the signaling pathways mediated by pY294, pY404, or pY451, are solely essential for RET/PTC1-induced tumor formation.
引用
收藏
页码:8166 / 8172
页数:7
相关论文
共 12 条
[1]   INOSITOL PHOSPHATES AND CELL SIGNALING [J].
BERRIDGE, MJ ;
IRVINE, RF .
NATURE, 1989, 341 (6239) :197-205
[2]   Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice [J].
Cho, JY ;
Sagartz, JE ;
Capen, CC ;
Mazzaferri, EL ;
Jhiang, SM .
ONCOGENE, 1999, 18 (24) :3659-3665
[3]   Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas [J].
Jhiang, SM ;
Sagartz, JE ;
Tong, Q ;
ParkerThornburg, J ;
Capen, CC ;
Cho, JY ;
Xing, SH ;
Ledent, C .
ENDOCRINOLOGY, 1996, 137 (01) :375-378
[4]   The RET proto-oncogene in human cancers [J].
Jhiang, SM .
ONCOGENE, 2000, 19 (49) :5590-5597
[5]   Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I ret transgenic mouse lines [J].
Kato, M ;
Liu, W ;
Akhand, AA ;
Dai, Y ;
Ohbayashi, M ;
Tuzuki, T ;
Suzuki, H ;
Isobe, K ;
Takahashi, M ;
Nakashima, I .
ONCOGENE, 1999, 18 (03) :837-842
[6]  
KATO M, 2002, ONCOGENE, V62, P2414
[7]   Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53 mice [J].
Powell, DJ ;
Russell, JP ;
Li, GQ ;
Kuo, BA ;
Fidanza, V ;
Huebner, K ;
Rothstein, JL .
ONCOGENE, 2001, 20 (25) :3235-3246
[8]  
Santoro M, 1996, ONCOGENE, V12, P1821
[9]   Ganglioneuromas and renal anomalies are induced by activated RETMEN2B in transgenic mice [J].
Sweetser, DA ;
Froelick, GJ ;
Matsumoto, AM ;
Kafer, KE ;
Marck, B ;
Palmiter, RD ;
Kapur, RP .
ONCOGENE, 1999, 18 (04) :877-886
[10]   RET oncogene activation in papillary thyroid carcinoma [J].
Tallini, G ;
Asa, SL .
ADVANCES IN ANATOMIC PATHOLOGY, 2001, 8 (06) :345-354